Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
$30.29
At close: May 16, 4:05 PM EDT
$30.26
-0.03-0.10%
Pre-Market: May 16, 4:05 PM EDT
Comments
Loading...
Xenon Pharmaceuticals Analyst Ratings and Price Targets | NASDAQ:XENE | Benzinga
Xenon Pharmaceuticals Inc has a consensus price target of $55.37 based on the ratings of 20 analysts. The high is $67 issued by Deutsche Bank on February 11, 2025. The low is $46 issued by SVB Leerink on August 11, 2022. The 3 most-recent analyst ratings were released by Evercore ISI Group, Wells Fargo, and RBC Capital on May 14, 2025, May 13, 2025, and May 13, 2025, respectively. With an average price target of $52.33 between Evercore ISI Group, Wells Fargo, and RBC Capital, there's an implied 72.95% upside for Xenon Pharmaceuticals Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Evercore ISI Group
Wells Fargo
RBC Capital
HC Wainwright & Co.
Needham
1calculated from analyst ratings
Analyst Ratings for Xenon Pharmaceuticals
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 05/14/2025 | Buy Now | 81.76% | Evercore ISI Group | Cory Kasimov68% | → $55 | Initiates | → Outperform | Get Alert |
| 05/13/2025 | Buy Now | 55.32% | Wells Fargo | Mohit Bansal66% | $50 → $47 | Maintains | Overweight | Get Alert |
| 05/13/2025 | Buy Now | 81.76% | RBC Capital | Brian Abrahams48% | $58 → $55 | Maintains | Outperform | Get Alert |
| 05/13/2025 | Buy Now | 75.15% | HC Wainwright & Co. | Douglas Tsao49% | $53 → $53 | Reiterates | Buy → Buy | Get Alert |
| 05/13/2025 | Buy Now | 81.76% | Needham | Serge Belanger65% | $60 → $55 | Maintains | Buy | Get Alert |
| 05/13/2025 | Buy Now | 81.76% | Chardan Capital | Rudy Li33% | $55 → $55 | Maintains | Buy | Get Alert |
| 05/07/2025 | Buy Now | 81.76% | Chardan Capital | Rudy Li33% | → $55 | Initiates | → Buy | Get Alert |
| 04/17/2025 | Buy Now | 71.84% | Goldman Sachs | Paul Choi58% | $60 → $52 | Maintains | Buy | Get Alert |
| 02/24/2025 | Buy Now | 75.15% | HC Wainwright & Co. | Douglas Tsao49% | $53 → $53 | Reiterates | Buy → Buy | Get Alert |
| 02/11/2025 | Buy Now | 121.41% | Deutsche Bank | David Hoang39% | → $67 | Initiates | → Buy | Get Alert |
| 12/12/2024 | Buy Now | 75.15% | HC Wainwright & Co. | Douglas Tsao49% | $53 → $53 | Reiterates | Buy → Buy | Get Alert |
| 11/13/2024 | Buy Now | 75.15% | HC Wainwright & Co. | Douglas Tsao49% | $53 → $53 | Reiterates | Buy → Buy | Get Alert |
| 11/13/2024 | Buy Now | 98.28% | Needham | Serge Belanger65% | $60 → $60 | Reiterates | Buy → Buy | Get Alert |
| 10/10/2024 | Buy Now | 65.23% | Raymond James | Danielle Brill41% | → $50 | Reinstates | → Outperform | Get Alert |
| 10/01/2024 | Buy Now | 75.15% | HC Wainwright & Co. | Douglas Tsao49% | → $53 | Initiates | → Buy | Get Alert |
| 09/03/2024 | Buy Now | 81.76% | RBC Capital | Brian Abrahams48% | $55 → $55 | Reiterates | Outperform → Outperform | Get Alert |
| 08/12/2024 | Buy Now | 98.28% | Needham | Serge Belanger65% | $62 → $60 | Maintains | Buy | Get Alert |
| 08/09/2024 | Buy Now | 114.81% | Cantor Fitzgerald | Josh Schimmer50% | $65 → $65 | Reiterates | Overweight → Overweight | Get Alert |
| 08/09/2024 | Buy Now | 61.93% | Wedbush | Laura Chico46% | $50 → $49 | Maintains | Outperform | Get Alert |
| 06/18/2024 | Buy Now | 81.76% | RBC Capital | Brian Abrahams48% | $55 → $55 | Reiterates | Outperform → Outperform | Get Alert |
| 05/10/2024 | Buy Now | 104.89% | Needham | Serge Belanger65% | $62 → $62 | Maintains | Buy | Get Alert |
| 05/10/2024 | Buy Now | 98.28% | Citigroup | David Hoang39% | $62 → $60 | Maintains | Buy | Get Alert |
| 05/10/2024 | Buy Now | 65.23% | Wedbush | Laura Chico46% | $51 → $50 | Maintains | Outperform | Get Alert |
| 04/12/2024 | Buy Now | 104.89% | Needham | Serge Belanger65% | $62 → $62 | Reiterates | Buy → Buy | Get Alert |
| 04/10/2024 | Buy Now | 114.81% | Cantor Fitzgerald | Josh Schimmer50% | → $65 | Reiterates | Overweight → Overweight | Get Alert |
| 03/01/2024 | Buy Now | 81.76% | RBC Capital | Brian Abrahams48% | $56 → $55 | Maintains | Outperform | Get Alert |
| 03/01/2024 | Buy Now | 68.54% | Wedbush | Laura Chico46% | $46 → $51 | Maintains | Outperform | Get Alert |
| 03/01/2024 | Buy Now | 104.89% | Needham | Serge Belanger65% | $50 → $62 | Maintains | Buy | Get Alert |
| 01/04/2024 | Buy Now | 104.89% | Citigroup | David Hoang39% | → $62 | Initiates | → Buy | Get Alert |
| 01/02/2024 | Buy Now | 85.06% | B of A Securities | Jason Gerberry59% | $52 → $56 | Maintains | Buy | Get Alert |
| 12/18/2023 | Buy Now | 104.89% | Stifel | Stephen Willey48% | $53 → $62 | Maintains | Buy | Get Alert |
| 12/08/2023 | Buy Now | 108.2% | Baird | Brian Skorney57% | → $63 | Initiates | → Outperform | Get Alert |
| 11/28/2023 | Buy Now | 85.06% | RBC Capital | Brian Abrahams48% | $51 → $56 | Maintains | Outperform | Get Alert |
| 11/09/2023 | Buy Now | 52.02% | Wedbush | Laura Chico46% | $47 → $46 | Maintains | Outperform | Get Alert |
| 10/24/2023 | Buy Now | — | Cantor Fitzgerald | Josh Schimmer50% | — | Assumes | → Overweight | Get Alert |
| 09/22/2023 | Buy Now | 68.54% | RBC Capital | Brian Abrahams48% | → $51 | Reiterates | Outperform → Outperform | Get Alert |
| 08/22/2023 | Buy Now | 91.67% | Cantor Fitzgerald | Charles Duncan68% | → $58 | Reiterates | Overweight → Overweight | Get Alert |
| 08/10/2023 | Buy Now | 55.32% | Wedbush | Laura Chico46% | → $47 | Reiterates | Outperform → Outperform | Get Alert |
| 08/10/2023 | Buy Now | 65.23% | Needham | Serge Belanger65% | → $50 | Reiterates | Buy → Buy | Get Alert |
| 07/17/2023 | Buy Now | 68.54% | RBC Capital | Brian Abrahams48% | → $51 | Reiterates | Outperform → Outperform | Get Alert |
| 06/21/2023 | Buy Now | 91.67% | Cantor Fitzgerald | Charles Duncan68% | → $58 | Reiterates | Overweight → Overweight | Get Alert |
| 06/15/2023 | Buy Now | 61.93% | Guggenheim | Yatin Suneja47% | → $49 | Reiterates | Buy → Buy | Get Alert |
| 05/10/2023 | Buy Now | 55.32% | Wedbush | Laura Chico46% | $44 → $47 | Maintains | Outperform | Get Alert |
| 04/25/2023 | Buy Now | 91.67% | Cantor Fitzgerald | Charles Duncan68% | → $58 | Initiates | → Overweight | Get Alert |
| 04/25/2023 | Buy Now | 81.76% | JP Morgan | Tessa Romero56% | $54 → $55 | Maintains | Overweight | Get Alert |
| 04/21/2023 | Buy Now | 65.23% | Needham | Serge Belanger65% | → $50 | Reiterates | → Buy | Get Alert |
| 03/22/2023 | Buy Now | 68.54% | RBC Capital | Brian Abrahams48% | → $51 | Reiterates | → Outperform | Get Alert |
| 03/02/2023 | Buy Now | 65.23% | Needham | Serge Belanger65% | $48 → $50 | Maintains | Buy | Get Alert |
| 01/31/2023 | Buy Now | 68.54% | RBC Capital | Brian Abrahams48% | $49 → $51 | Maintains | Outperform | Get Alert |
| 12/14/2022 | Buy Now | 98.28% | Goldman Sachs | Paul Choi58% | → $60 | Initiates | → Buy | Get Alert |
| 12/12/2022 | Buy Now | — | Cowen & Co. | Joseph Thome26% | — | Initiates | → Outperform | Get Alert |
| 11/28/2022 | Buy Now | 65.23% | Wells Fargo | Mohit Bansal66% | → $50 | Initiates | → Overweight | Get Alert |
| 11/11/2022 | Buy Now | 61.93% | Guggenheim | Yatin Suneja47% | $53 → $49 | Maintains | Buy | Get Alert |
| 10/19/2022 | Buy Now | 71.84% | Raymond James | Danielle Brill41% | → $52 | Initiates | → Outperform | Get Alert |
| 10/11/2022 | Buy Now | 61.93% | RBC Capital | Brian Abrahams48% | $46 → $49 | Maintains | Outperform | Get Alert |
| 08/29/2022 | Buy Now | — | B of A Securities | Jason Gerberry59% | — | Initiates | → Buy | Get Alert |
| 08/11/2022 | Buy Now | 52.02% | SVB Leerink | Marc Goodman72% | $40 → $46 | Maintains | Outperform | Get Alert |
| 08/10/2022 | Buy Now | 52.02% | RBC Capital | Brian Abrahams48% | $41 → $46 | Maintains | Outperform | Get Alert |
| 07/21/2022 | Buy Now | 81.76% | JP Morgan | Tessa Romero56% | → $55 | Initiates | → Overweight | Get Alert |
| 06/27/2022 | Buy Now | 35.49% | Wedbush | Laura Chico46% | $47 → $41 | Maintains | Outperform | Get Alert |
FAQ
What is the target price for Xenon Pharmaceuticals (XENE) stock?
The latest price target for Xenon Pharmaceuticals (NASDAQ:XENE) was reported by Evercore ISI Group on May 14, 2025. The analyst firm set a price target for $55.00 expecting XENE to rise to within 12 months (a possible 81.76% upside). 20 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Xenon Pharmaceuticals (XENE)?
The latest analyst rating for Xenon Pharmaceuticals (NASDAQ:XENE) was provided by Evercore ISI Group, and Xenon Pharmaceuticals initiated their outperform rating.
When was the last upgrade for Xenon Pharmaceuticals (XENE)?
There is no last upgrade for Xenon Pharmaceuticals
When was the last downgrade for Xenon Pharmaceuticals (XENE)?
There is no last downgrade for Xenon Pharmaceuticals.
When is the next analyst rating going to be posted or updated for Xenon Pharmaceuticals (XENE)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Xenon Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Xenon Pharmaceuticals was filed on May 14, 2025 so you should expect the next rating to be made available sometime around May 14, 2026.
Is the Analyst Rating Xenon Pharmaceuticals (XENE) correct?
While ratings are subjective and will change, the latest Xenon Pharmaceuticals (XENE) rating was a initiated with a price target of $0.00 to $55.00. The current price Xenon Pharmaceuticals (XENE) is trading at is $30.26, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.
